Glial cell-derived neurotrophic factor receptor alpha 1 (GFRalpha1)

Glial cell-derived neurotrophic factor receptor alpha 1 (GFRalpha1) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein that serves as the primary binding partner for Glial Cell-Derived Neurotrophic Factor (GDNF) (Airaksinen & Saarma, 2002, Nature Reviews Neuroscience). Upon binding GDNF, GFRalpha1 recruits the RET receptor tyrosine kinase, leading to RET dimerization and autophosphorylation, which initiates signaling cascades like the PI3K and MAPK pathways (UniProt P56159). This receptor complex is essential for the survival and maintenance of midbrain dopaminergic neurons, as well as the development of the enteric nervous system and the kidneys (Ibanez, 2013, Cold Spring Harbor Perspectives in Biology). In clinical contexts, GFRalpha1 is a high-interest target for Parkinson’s disease, where GDNF-based therapies aim to restore degenerating dopaminergic pathways (Whone et al., 2019, Brain). Therapeutic approaches include direct infusion of recombinant GDNF, small molecule agonists like XIB4035, and gene therapy using adeno-associated viruses (AAV) to provide sustained neurotrophic support (Allen et al., 2013, Journal of Neuroscience Research). However, drug delivery remains a significant hurdle due to the blood-brain barrier and the need for localized action to avoid peripheral side effects (Bespalov & Saarma, 2007, Trends in Pharmacological Sciences).

Other names

GDNF receptor alpha-1GDNFR-alphaRET ligand 1RETL1TRNR1TGF-beta-related neurotrophic factor receptor 1

Agonism of the GFRalpha1-RET complex to activate downstream PI3K/Akt and MAPK/ERK signaling pathways for neuroprotection and neuronal recovery.